Letters Section Editor: Robert M. Golub, MD, Senior Editor.
To the Editor: In their study of patterns of drug therapy and underlying mortality risk in patients with heart failure, Dr Lee and colleagues1 concluded that patients with congestive heart failure who have the highest risk of mortality have the lowest likelihood of receiving effective drugs, such as angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs). These paradoxical findings may reflect 2 methodological problems in this study.
Suissa S. Risk-Treatment Mismatch for Heart Failure. JAMA. 2005;294(24):3087-3088. doi:10.1001/jama.294.24.3087-a